Systemic drug delivery is the current clinically preferred route for cancer therapy. However,
challenges associated with tumor localization and off-tumor toxic effects limit the clinical …

Tumor excision is a necessary life-saving procedure in most solid cancers. However,
surgery and the days before and following it, known as the immediate perioperative period …

Polymeric nanoparticles (NPs), specifically those comprised of biodegradable and
biocompatible polyesters, have been heralded as a game‐changing drug delivery platform …

The human epidermal growth factor receptor 2 (HER2) is a transmembrane tyrosine kinase
receptor and tumor-associated antigen abnormally expressed in various types of cancer …

Head and neck squamous cell carcinoma (HNSCC) is a challenging disease to treat
because of typically late-stage diagnoses and tumor formation in difficult-to-treat areas …

Background: Antibody–drug conjugates (ADCs) represent potent cancer therapies that
deliver highly toxic drugs to tumor cells precisely, thus allowing for targeted treatment and …

Immune checkpoint therapy (ICT) for cancer can yield dramatic clinical responses; however,
these may only be observed in a minority of patients. These responses can be further limited …

This review summarizes development of large surface area microparticle paclitaxel (LSAM-
PTX) and docetaxel (LSAM-DTX) for local treatment of primary carcinomas with emphasis on …

Scientists are exploring new approaches to overcome cancer, and nanovaccines have
emerged as one of the most promising tools in the fight against cancer. This review aimed to …

Background: Cellular heterogeneity presents a significant challenge to cancer treatment.
Antibody therapies targeting individual tumor-associated antigens can be extremely effective …